ACE inhibitors may be of some benefit in cancer (Nakagawa et al, 1995; Reddy et al, 1995; Lever et al, 1998; Yoshiji et al, 2002), mainly acting via their antiangiogenic potential and as more general zinc metalloprotease inhibitors, independently of the RAS and of ACE inhibition. This evidence concerns the gene ACE and cancer.